Status
Conditions
Treatments
About
Adolescents living with Human Immunodeficiency Virus (ALHIV) are at an increased risk of experiencing psychological distress and adverse mental health outcomes, particularly in low- to middle-income countries (LMICs). Although interventions aimed at promoting resilience have demonstrated potential in enhancing psychosocial outcomes among adolescents with chronic illnesses in high-income settings, there is a paucity of evidence from LMICs. This study protocol aims to outline a comprehensive framework for evaluating the feasibility, acceptability, and effectiveness of the Promoting Resilience in Stress Management (PRISM) intervention in comparison to standard psychosocial care among ALHIV in a LMIC, such as Eswatini (formerly known as Swaziland). Additionally, it seeks to gather qualitative insights from both participants and PRISM coaches regarding the PRISM program. Exploratory outcomes under investigation are psychological distress, resilience, and HIV health-related quality of life. We hypothesise that:
Full description
This study employs an explanatory sequential mixed-methods design to rigorously evaluate the Promoting Resilience in Stress Management (PRISM) intervention. In the initial quantitative phase, a single-site, single-blind, pilot randomized controlled trial (RCT) will be conducted. A sample of (n=140) ALHIV will be recruited and randomly assigned to either the PRISM intervention arm or a control arm receiving standard psychosocial care. The PRISM intervention, a manualized, skills-based training program, originally comprises six 30-60-minute, one-on-one sessions designed to enhance resilience resources, including stress management, goal-setting, cognitive reframing, and meaning-making, in adolescents and young adults (AYAs). For the purposes of this trial, the PRISM intervention will be adapted to consist of three 60-minute sessions, delivered at intervals of 1-2 weeks based on participant preference. Participants in both arms will complete validated survey instruments to assess exploratory outcomes, including psychological distress, resilience, and HIV-related quality of life. Data collection will occur at baseline (T0), and at 3 months (T1), 6 months (T2), 9 months (T3), and 12 months (T4) post-enrollment. The researchers will then evaluate the feasibility, acceptability, and effectiveness of the PRISM intervention based on these outcomes.
In the second phase of the study, an Exploratory-Descriptive Qualitative (EDQ) research design will be employed to investigate the experiences and perceptions of participants engaged in the PRISM program. Data collection will involve the use of semi-structured interview guides administered to nurse PRISM coaches and a purposively selected sample of ALHIV from the intervention arm of the pilot clinical trial. The collected data will undergo rigorous thematic analysis to elucidate key insights into the participants' experiences and perceptions of the PRISM intervention, thereby contributing to a deeper understanding of its implementation and impact.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria for the Clinical Trial:
Exclusion Criteria for the Clinical Trial:
Inclusion criteria for a support person:
The PRISM intervention requires a caretaker or parent to be invited by the study participant to join the third session.
• Parent or caretaker should be ≥ 18 years of age and consent to participation.
Exclusion criteria for a support person:
• A parent or caretaker who refuses to participate.
Eligibility Criteria for Participation in Semi-Structured Interviews Post Intervention
Inclusion criteria for participants:
Exclusion criteria for participants:
• Participants who meet the inclusion criteria but are unwilling to provide informed consent or assent and/or parental consent.
Inclusion criteria for implementers:
• PRISM coaches who offered all sessions of the PRISM intervention and who will be willing to be audio-taped.
Exclusion criteria for implementers:
• PRISM coaches who meet the inclusion criteria but are unwilling to provide informed consent to participate.
Primary purpose
Allocation
Interventional model
Masking
140 participants in 2 patient groups
Loading...
Central trial contact
Mduduzi C. Shongwe, PhD; Musa L. Nhlabatsi, MSc
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal